<DOC>
	<DOCNO>NCT03036098</DOCNO>
	<brief_summary>The purpose study determine whether investigational immunotherapy nivolumab combination ipilimumab effective standard care chemotherapy treat patient previously untreated inoperable metastatic urothelial cancer .</brief_summary>
	<brief_title>Study Nivolumab Combination With Ipilimumab Compared Standard Care Chemotherapy Treatment Patients With Untreated Inoperable Metastatic Urothelial Cancer</brief_title>
	<detailed_description />
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>For information regard BristolMyers Squibb Clinical Trial participation , please visit www.BMSStudyConnect.com Metastatic inoperable urothelial cancer Must least 1 lesion measurable disease Must full activity , limited , must able walk carry activity light house work office work No prior systemic chemotherapy treatment metastatic setting Patients disease suitable local therapy administer curative intent Patients active brain metastasis leptomeningeal metastasis Patients active , know suspected autoimmune disease Prior treatment antiPD1 , antiPDL1 , antiPDL2 , antiCD137 , antiCTLA4 antibody , antibody drug specifically target Tcell costimulation checkpoint pathways Other protocol define inclusion/exclusion criterion could apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>